News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
756,387 Results
Type
Article (70777)
Company Profile (321)
Press Release (685289)
Section
Business (209650)
Career Advice (3408)
Deals (38835)
Drug Delivery (126)
Drug Development (85403)
Employer Resources (185)
FDA (17358)
Job Trends (16772)
News (363602)
Policy (37128)
Tag
Academia (2979)
Alliances (51441)
Alzheimer's disease (1423)
Approvals (17309)
Artificial intelligence (232)
Bankruptcy (379)
Best Places to Work (12586)
Biotechnology (225)
Breast cancer (240)
Cancer (1837)
Cardiovascular disease (149)
Career advice (2882)
CAR-T (140)
Cell therapy (396)
Clinical research (68466)
Collaboration (718)
Compensation (380)
COVID-19 (2835)
C-suite (174)
Data (1663)
Diabetes (234)
Diagnostics (6813)
Earnings (84088)
Employer resources (159)
Events (116613)
Executive appointments (602)
FDA (18300)
Funding (645)
Gene therapy (278)
GLP-1 (772)
Government (5053)
Healthcare (20813)
Infectious disease (2958)
Inflammatory bowel disease (133)
Interviews (654)
IPO (17492)
Job creations (4654)
Job search strategy (2368)
Layoffs (518)
Legal (9194)
Lung cancer (276)
Manufacturing (263)
Medical device (14486)
Medtech (14491)
Mergers & acquisitions (21725)
Metabolic disorders (632)
Neuroscience (1878)
NextGen: Class of 2025 (7473)
Non-profit (5074)
Northern California (2137)
Obesity (354)
Opinion (258)
Patents (173)
People (59790)
Phase I (21170)
Phase II (29830)
Phase III (22632)
Pipeline (739)
Postmarket research (3088)
Preclinical (9017)
Radiopharmaceuticals (263)
Rare diseases (358)
Real estate (6482)
Regulatory (24776)
Research institute (2636)
Resumes & cover letters (539)
Southern California (1838)
Startups (3963)
United States (19336)
Vaccines (721)
Weight loss (267)
Date
Today (158)
Last 7 days (693)
Last 30 days (2832)
Last 365 days (36753)
2025 (4685)
2024 (37486)
2023 (42556)
2022 (53925)
2021 (58717)
2020 (57658)
2019 (51306)
2018 (39090)
2017 (35766)
2016 (35438)
2015 (44074)
2014 (39633)
2013 (34282)
2012 (30066)
2011 (30656)
2010 (29100)
Location
Africa (1109)
Arizona (195)
Asia (45064)
Australia (7777)
California (4937)
Canada (1740)
China (418)
Colorado (224)
Connecticut (246)
Europe (104075)
Florida (709)
Georgia (175)
Illinois (505)
Indiana (273)
Maryland (789)
Massachusetts (3801)
Michigan (218)
Minnesota (354)
New Jersey (1397)
New York (1397)
North Carolina (943)
Northern California (2137)
Ohio (183)
Pennsylvania (1118)
South America (1491)
Southern California (1838)
Texas (721)
Utah (150)
Washington State (488)
756,387 Results for "ac immune sa".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024
AC Immune SA announced that Company Management will participate in a fireside chat and one-on-one investor meetings during the Jefferies 2024 Global Healthcare Conference, taking place in-person in New York on June 5-6, 2024.
May 28, 2024
·
3 min read
Genetown
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
Takeda and AC Immune SA announced an exclusive, worldwide option and license agreement for AC Immune’s active immunotherapies targeting toxic forms of amyloid beta, including ACI-24.060 for the treatment of Alzheimer’s disease.
May 13, 2024
·
12 min read
Business
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
AC Immune SA, a clinical-stage biopharmaceutical company pioneering the development of precision medicine approaches for the diagnosis, treatment, and prevention of neurodegenerative diseases, reported results for the quarter ended March 31, 2024, and provided a corporate update.
May 13, 2024
·
9 min read
Press Releases
AC Immune to Present at the Jefferies 2024 London Healthcare Conference
November 13, 2024
·
3 min read
Press Releases
AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome
December 11, 2024
·
7 min read
AC Immune Announces Upcoming Presentations at AD/PD™ 2024
AC Immune SA announced upcoming presentations highlighting its precision medicine pipeline at the International Conference on Alzheimer’s and Parkinson’s Diseases, taking place in Lisbon, Portugal March 5-9, 2024.
February 22, 2024
·
5 min read
Business
Takeda Inks Potential $2.2B Deal for AC Immune’s Alzheimer’s Immunotherapy
Takeda on Monday said it is paying AC Immune $100 million upfront for an option on a Phase Ib/II Alzheimer’s disease candidate that could activate the immune system to clear amyloid beta plaques.
May 13, 2024
·
2 min read
·
Nick Paul Taylor
Business
AC Immune SA Appoints New Chief Medical Officer
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, announced the appointment of Nuno Mendonça, MD.
July 26, 2023
·
5 min read
Business
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering the development of precision medicine approaches for the diagnosis, treatment, and prevention of neurodegenerative diseases, today reported results for the year ended December 31, 2023, and provided a corporate update.
March 14, 2024
·
13 min read
Rare diseases
Novo’s Bispecific for Hemophilia Aces Phase III Pediatric Trial
Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III FRONTIER3 trial. The company plans to file for approval this year, hoping to compete in the hemophilia A space with Roche’s
blockbuster
Hemlibra.
February 7, 2025
·
2 min read
·
Dan Samorodnitsky
1 of 75,639
Next
